ARTCLINE, a biomedical company specialising in the development of immune cell treatments for septic shock, has announced the appointment of Peter Llewellyn-Davies as Chairman of its Supervisory Board.
Llewellyn-Davies brings significant expertise in Europe’s biotechnology sector to his role as Chairman, as well as multiple decades of experience in senior leadership, investment and advisory roles. He is currently founder and CEO of Accellerate Partners, as well as the founder and acting president of Austrian biotech industry association BIOTECH AUSTRIA.
Previous roles held by Llewellyn-Davies include founder of invIOs, CEO of APEIRON Biologics, Chief Financial Officer (CFO) and Chief Business Officer of Medigene and CFO of WILEX. He is currently a member of the supervisory board of Shield Therapeutics.
ARTCLINE’s patented ARTICE therapy uses allogeneic donor immune cells for the treatment of immune dysfunction in cases of septic shock. The therapy is currently being studied in the ReActIF-ICE trial. All of the therapy’s components have already been approved by Germany’s regulatory bodies: ARTCLINE plans to begin market launch for ARTICE in late 2026.
Llewellyn-Davies said: “There is an enormous unmet medical need for septic shock therapies. Every day, more than 200 people die from this disease in Germany alone, and there are currently no adequate treatment options available.
“In my opinion, ARTCLINE’s ARTICE therapy represents a highly innovative approach and holds the potential to deliver a genuine therapeutic breakthrough: by relieving and regenerating the immune system, mortality may be reduced, particularly in the second phase of immune dysfunction.”
